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Abstract
Background:  Papillary thyroid microcarcinomas are tumors often found accidentally after
thyroidectomy for other thyroid disorders.
Methods: Patients with enlarged lateral cervical masses, with unknown thyroid disease, found to
have metastases from papillary thyroid carcinoma ≤10 mm in diameter, were compared to patients
operated on for nodular or multinodular goiter, who were incidentally found to have papillary
thyroid microcarcinomas.
Results: Group A included 24 patients with an enlarged lateral cervical mass whereas group B
included 30 patients presenting with nodular or multinodular goiter. Patients in both groups
underwent surgery. After thyroidectomy and lymph node dissection, pathology revealed multifocal
papillary carcinomas of 1–10 mm, with invasion of the thyroid capsule and surrounding soft tissue
in most of the cases in group A. Two patients presented with distant metastases at diagnosis which
were surgically removed. During follow up, 3 patients (12.5%) presented with new cervical
metastases which were surgically removed or treated with additional radioactive iodine. At last
follow-up, all patients were alive. In contrast, all patients in group B had unifocal papillary thyroid
carcinoma 1–10 mm in maximum diameter, with no infiltration or extension into the adjacent
tissue, or cervical lymph node metastases.
Conclusion: Two groups of papillary thyroid microcarcinomas characterized by different clinical
and biological behaviours are identified. Significant differences were found between these groups
concerning the age, tumor size, number of tumor foci, lymph nodes metastases and extrathyroidal
extension of the tumor. Papillary thyroid carcinomas of small (≤10 mm) size may have aggressive
behaviour or be metastatic, and this subgroup should be treated and followed up as are other large,
differentiated thyroid cancers.
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Background
Papillary microcarcinomas of the thyroid are defined as
tumors 10 mm or less in diameter [1,2] which are often
not detectable upon clinical examination, but are fre-
quently found accidentally [3] after thyroidectomy for
other thyroid disorders. Their behaviour is benign most of
the time. Many are not diagnosed during the patient's life-
time. It has been reported that occult papillary carcinomas
may be found at autopsy in up to 24% of the cases [4,5].
They are considered to be a subgroup of well-differenti-
ated carcinomas of the thyroid and it was believed that
they could rarely cause cervical or distant metastases.
However papillary microcarcinomas may present in a
more aggressive manner with lymph nodes or even distant
metastases [6,7] and, in many reports on this problem,
lymph node metastases or extrathyroidal extension were
found in up to 40.3% of the cases [8-12]
Patients with nodular or multinodular goiters may have
papillary thyroid microcar-cinomas that are found inci-
dentally after thyroidectomy. We compared results from
consecutive cases of thyroidectomies which were per-
formed to remove goiter where small carcinomas were
found incidentally after surgery to cases of carcinomas of
the thyroid ≤10 mm in diameter diagnosed after they had
metastasized to cervical lymph nodes in patients with
unknown thyroid disease.
Patients and methods
Twenty-four patients including 19 women and 5 men
aged 16–63 years, (mean age 39.96 ± 13.91 years) were
referred to the internal medicine or surgical outpatients'
clinic at Theagenion Cancer Hospital from 1993–2005
because of a neck mass that was painless (group A). Of
these masses, 15 were on the right, and 9 on the left side;
they measured 3–10 cm in maximum diameter. Clinical
examination revealed the existence of one or more cervi-
cal lymph nodes in all patients and absence of goitre. Thy-
roid function tests were normal. No patient had
previously received head and neck irradiation therapy, or
had a known history of thyroid disease.
Inflammatory diseases that can cause cervical lymphaden-
opathy were excluded in all patients. An ultrasound scan
of the lateral cervical mass revealed 2 large cystic forma-
tions with few solid elements in 2 patients, which were
considered to be bran-chial cysts. In 22 patients, multiple
enlarged solid hypoechoic masses, some with areas of
fusion were observed, which probably represented lymph
nodes.
Fine needle aspiration (FNA) followed by cytological
examination of the aspirate was performed in 5 patients,
while 19 patients had a lymph node dissection followed
by histological examination of the node. In all patients,
cytology or pathology revealed metastases from papillary
thyroid carcinoma, a finding that led to the decision for
total thyroidectomy and lymph node dissection. As the
original examination was performed in the non-special-
ized clinic, ultrasound scan of the thyroid was pre-opera-
tively performed in only 17 patients, after the diagnosis of
metastatic papillary thyroid carcinoma was established;
this revealed a single small hypoechoic nodule in 8
patients and 2 nodules in 4 patients, all sized 4–10 mm in
diameter, and increased intranodular vascularization, one
hyperechoic nodule 10 mm in diameter in 2 patients, and
normal findings in 3 patients. Unfortunately no preoper-
ative thyroid US was performed in the remaining 7
patients. In addition, 16 of the 24 patients, underwent
thyroid 99Tc scintigraphy which showed a small cold nod-
ule in 4, increased uptake of radionucleotide in 3, proba-
bly representing small hot nodules, whereas normal
thyroid was found in 9 patients. After the metastases to
cervical lymph nodes was proven to be from the thyroid
through lymph node FNA or lymph node dissection, all
patients underwent total thyroidectomy, central depart-
ment lymph node dissection and ipsilateral lymph node
dissection. Moreover, in 3 patients lymph node dissection
of the upper mediastinum was performed. At this point
the patients were referred to the Endocrine clinic for fur-
ther management.
Ablation therapy with a standard radioactive iodine131
dose of 3700 MBq was given, followed by a whole body
scan. In all patients suppressive thyroxine therapy at a
dose of 1.5–2 μg/kg/day was given.
The second group included in the study (group B), com-
prised 30 consecutive patients (27 females) aged 28–70
years (mean 47.17 ± 13.17 years) who were similarly
referred to the endocrine clinic by the surgery department
after they had undergone total or near total thyroidec-
tomy for multinodular goiter, and in whom pathological
examination had revealed the incidental presence of a
papillary microcarcinoma. The above patients underwent
surgery, because one or more nodules had significantly
increased in size during the last months; although they
had no signs of malignancy in the ultrasound and the FNA
was negative. During thyroidectomy inspection of lymph
nodes status, both of central and lateral compartments
was performed and it was negative for metastases. This
second group served as the control group. At referral in the
endocrine clinic, a neck ultrasound was performed which
did not show the presence of metastatic lymph nodes.
Thyroid bed uptake was under 1.5% in all patients. Thy-
roxine therapy at a dose of 1.5–2 μg/kg/day was given. No
patient in this group received ablation therapy with radi-
oactive 131I.Thyroid Research 2008, 1:8 http://www.thyroidresearchjournal.com/content/1/1/8
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Postoperatively, in both groups, TSH and thyrogobulin
(Tg) were measured after thyroxine withdrawal (table 1,
2).
Pathology
All thyroid tissue samples were oriented, cut in parallel
longitudinal slices 5 mm thick and fixed in 10% neutral
buffered formalin for 24 hours. After fixation the samples
were finely cut and paraffin embedded. For solitary encap-
sulated nodules measuring up to 5 cm, found only in
group B, an additional section was taken for each addi-
tional centimeter in diameter, including the nodule cap-
sule and adjacent thyroid tissue. For multinodular goiters,
one section of each nodule (up to five nodules) was taken
and more than one section for larger nodules [13]. Sam-
ples were routinely processed after paraffin-embedding.
Normal tissue adjacent to neoplastic areas was also evalu-
ated. The assessment of the diameter of the lesion was
done microscopically. The tissue samples were all exam-
ined in the same Department by two pathologists who
were consistent in looking for coincidental microcarcino-
mas. Pathologists were not aware of the clinical data.
Statistical analysis
Statistical analysis of the differences between clinical and
histological variables between groups was conducted by
χ2 test or Student's t test. Significant levels were presented
as P values. Variables analyzed were: age, tumor size,
number of tumor foci, lymph node metastases at thyroid-
ectomy and invasion of thyroid parenchyma, thyroid cap-
sule, extrathyroidal invasion or vessels invasion.
Calculations were carried out using SPSS version 12.0.
Results were considered statistically significant when p
value was ≤ 0.05.
Results
In all patients in group A, with impalpable thyroid gland
and unknown thyroid disease, pathology confirmed the
existence of papillary carcinoma of the thyroid, 1–10 mm
in maximum diameter (mean 7.71 mm). In 10 cases
(41.7%), more than one tumor foci were identified
located in one lobe in 7 patients, and in both lobes in 3
patients. The carcinoma was entirely of the papillary type
in 9 cases (37.5%), while in the remaining 15 cases was
follicular variant of papillary thyroid carcinoma (Table 1).
In all tumors, the carcinoma cells showed the characteris-
tic nuclear morphology, with enlarged, crowded, clear
nuclei (ground glass), often with longitudinal nuclear
grooves. Psammoma bodies were found in 8 cases
(33.3%). In 11 cases (45.8%), the tumor infiltrated the
adjacent thyroid parenchyma, while in 8 (33.3%) it dis-
rupted the thyroid capsule, and in 4 cases it extended into
the surrounding adipose tissue (Table 1). In 16 patients
(66.6%), many new metastatic cervical lymph nodes were
found in both compartments. In most patients, lymph
node metastases showed the typical papillary pattern,
while in other cases mixed follicular-papillary morphol-
ogy was also observed. The metastatic foci, in all cases,
were of the same pattern with the primary tumor.
In all patients in group B pathology revealed unifocal pap-
illary thyroid carcinoma of 1–10 mm in maximum diam-
eter, (mean 5.3 mm). The carcinoma was entirely of the
papillary type in 25 cases (83.3%), while in the remaining
5 cases it was follicular variant of papillary thyroid carci-
noma. No infiltration to thyroid parenchyma and thyroid
capsule or extension into the adjacent tissue, or cervical
lymph node metastases were noted (Table 2). None of the
larger nodules identified in this group was malignant,
they all proved to be benign lesions.
In group A, serum thyroglobulin levels after thyroidec-
tomy ranged from 0.3–2630 ng/ml, median 8.2 ng/ml,
and TSH was 38.9–92.4 μU/ml (normal values 0.3–4 μU/
ml) on stopping LT4. Higher levels of serum thyroglobu-
lin appeared in patients with distant metastases (Table 1).
A whole body scan, which was performed 7 days after
ablation, revealed a large metastasis in the parapharyngeal
area in 1 patient (Fig. 1) and in the mediastinum in
another patient (Fig 2). Both patients underwent comple-
tion surgery. In group B, TSH was 36.5–79.8 μU/ml, and
serum thyroglobulin ranged from 0.3 to 1.0 ng/ml,
median 0.75 ng/ml after thyroxine withdrawal.
Statistical analyses between groups A and B revealed that
mean age at the diagnosis of thyroid cancer was higher in
patients of group B and this difference was borderline sig-
nificant (t = -1.95, p = 0.05). Tumor size was significantly
smaller in group B (t = 3.39, p = 0.001, table 2). Tg levels
were higher in group A (table 2). Significant differences
were found between group A and B when lymph node
metastases, extrathyroid extension of the tumor and
multifocality were compared (table 2).
Follow-up
The follow-up duration of the patients in our clinic was
34–140 months (mean 55.66 months) in group A and
38–130 months (mean 62 months) in group B. All
patients (in both groups) underwent clinical examination
and an ultrasound scan of the neck every 6 months (group
A) or 12 months (group B). Thyroid stimulating hor-
mone, FT4, and Tg [14], on thyroxine or after stimulation
with TSH [15] were measured annually; a whole body 131I
scan was performed when necessary. Four patients in
group A received additional radioactive iodine131I therapy
(3700–7400 MBq) due to persistent local disease. During
the follow up, and specifically 24–36 months after the ini-
tial treatment, 3 patients in group A presented with new
metastases in the cervical lymph nodes (one contralateral
of the initial disease) and received additional therapy withThyroid Research 2008, 1:8 http://www.thyroidresearchjournal.com/content/1/1/8
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Table 1: Surgery, pathology, and metastases in patients from group A
Patient Age Tumor size
(mm)
Pathology Infiltration/
Extension
Metastatic 
lymph nodes
Tg ** Metastases * Follow up
(mo)
Recurrence/
persistent 
disease
PA 50 10 P-f 5 27.6 Upper 
mediastinum
Lymph nodes
39 CLN
TZ 43 4 P-f Thyr capsule
Thyr 
parenchyma
24 3 . 7 5 1 -
KΠ 58 8 P-f - 1 59.3 41 -
GM 40 10 & 2 & 2 P-f Thyr capsule
Thyr 
parenchyma
40 . 4 3 6 -
MT 57 10 & 2 & 1 P-f Thyr capsule
Thyr 
parenchyma
74 3 . 0 7 5 C L N  c
SE 37 4 P - 11 1.9 60 -
KT 34 10 & 2 P Thyr 
parenchyma
Fatty tissue
3 19.5 140 CLN
KM 26 2 & 5 P - 1 0.8 56 _
AA 56 5 P - 1 25.7 34 CLN
LC 63 1 P-f - 2 0.7 46 -
HD 33 8 P-f Thyr capsule
Thyr 
parenchyma
35 . 9 4 8 -
HS 56 10 & 3 & 2 P-f Thyr 
parenchyma
Fatty tissue
13 . 7 3 4 -
MD 38 7 P-f - 1 7.7 44 -
TP 32 2 & 10 P - 3 0.5 38 -
SP 37 8 & 10 P Nodule capsule
Fatty tissue
95 0 3 . 0 L o w e r  
mediastinum
Lymph nodes
58 _
GK 24 7 & 8 P-f - 2 2631.0 Parapharyngeal 
area
48 _
HI 28 9 P-f - 1 5.3 36 -
ZS 57 10 P Nodule capsule 2 8.7 40 -
KA 21 7 P - 1 2.3 102 -Thyroid Research 2008, 1:8 http://www.thyroidresearchjournal.com/content/1/1/8
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radioactive iodine [16] or underwent lymph node dissec-
tion [17]. During the last follow up, all patients were alive
and free of disease. Patients in group B were also regularly
followed up originally at 6 months and subsequently at
12 month intervals by detailed ultrasound and Tg meas-
urements and none of them has so far presented with
local or distant metastases.
Discussion
Papillary thyroid microcarcinomas are small sized thyroid
tumors that belong to the group of well-differentiated low
risk carcinomas of the thyroid. They can be present in nor-
mal thyroids, just like in many of our patients. Many of
them are tumors with benign behavior that do not affect
patient survival and do not need supplementary radioac-
tive therapy. As these tumors remain small or even regress,
some authors suggest that incidentally found small papil-
lary carcinomas should be called occult papillary tumors
[18] instead of carcinomas. Similarly, a recent Annual
Cancer Meeting held at the Institute of Molecular Pathol-
ogy and Immunology of University of Porto, Porto, Portu-
gal raised the issue of re-naming of papillary thyroid
carcinomas, ≤ 1 cm in diameter (single focus), found inci-
dentally within the thyroid gland of an adult undergoing
thyroidectomy for some other reason, as "papillary micro-
tumors" [19]. Occasionally, despite their small size, pap-
illary thyroid tumors can give rise to cervical lymph node
metastases and, less often, distant metastases [7,20]. Met-
astatic lymph nodes usually appear as a solid mass in the
lateral neck. Cystic lymph node metastases are rare
[21,22]. Two of our patients presented with a lateral cystic
cervical mass, resembling a branchial cyst. A preoperative
diagnosis between a branchial cyst and a solitary cystic
lymph node metastasis from occult thyroid carcinoma
may be difficult [23,24]. It has been suggested that thy-
roglobulin measurements can be performed from the
aspirate of the cystic lesion and if this is measurable, then
a metastasis from a thyroid carcinoma is very likely [25].
Unfortunately this method was not applied in our study.
It should be stressed that lateral cervical masses may be of
thyroidal origin even in the absence of evident thyroid
disease [26] as was observed in three of our patients in
group A, who had very small tumors with a maximum
diameter of 1, 4 and 4 mm. This concept is not always
NG 16 9 P-f Thyr capsule
Thyr 
parenchyma
32 7 . 7 U p p e r  
mediastinum 
lymph nodes
56 CLN
PF 26 8 & 9 P-f Thyr capsule
Thyr 
parenchyma
8 134.0 Upper 
mediastinum 
lymph nodes
42 CLN
VA 58 8 & 5 P Thyr 
parenchyma
Fatty tissue
40 . 3 1 3 0 -
AS 42 8 P-f Thyr capsule
Thyr 
parenchyma
4 791.2 40 CLN
BE 27 5 P-f Thyr capsule
Thyr 
parenchyma
70 . 3 4 2
P: papillary, P-f: Papillary-follicular type, Thyr: Thyroid, CLN: cervical lymph nodes, c: controlateral of initial disease, metastatic lymph nodes, 
*Postoperative thyroglobulin on stopping LT4, ** Distant metastases diagnosed with the post-therapy WBS
Table 1: Surgery, pathology, and metastases in patients from group A (Continued)
Table 2: Pathology of papillary thyroid microcarcinomas and Tg in group A and B
Patients characteristics Group A, n = 24 Group B, n = 30 P
Mean age (years) 39.96 ± 13.91 47.17 ± 13.17 0.050
Mean tumor size * (mm) 7.71 ± 2.49 5.30 ± 2.67 0.001
% multifocality 10/24 (41.7%) 0/30 (0%) 0.000
% extrathyroid extension 4/24 (16.6%) 0/30 (0%) 0.000
% lymph nodes metastases 24/24 (100%) 0/30 (0%) 0.000
Tg **(ng/ml)
range 0.3 – 2630 0.3 – 1.0
median 8.2 0.75
* In the cases with multifocal disease we have calculated only the maximum tumor size. ** Postoperative thyroglobulin on stopping LT4Thyroid Research 2008, 1:8 http://www.thyroidresearchjournal.com/content/1/1/8
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obvious and can lead to misdiagnosis or delayed diagno-
sis and to unnecessary 2 step surgeries.
Although the risk of distant spread is certainly lower for
small tumors, sporadic cases of "occult" tumors with dis-
tant metastases have been reported [7,27,28]. Two of our
patients had distant metastases at diagnosis of the disease
(one in the parapharyngeal area and one in the lower
mediastinum, which were both surgically removed). It
should be noted that the absence of suspect clinical find-
ings in the thyroid does not exclude local or distant metas-
tases from small thyroid cancers, as was indeed observed
in our patients
Group A patients with small thyroid tumors did not differ
in their clinical behavior from patients with larger papil-
lary carcinomas of the thyroid. Therefore, we believe that
criteria other than size alone should be taken into consid-
eration when observing the clinical behavior of thyroid
tumors [6,11,12]. The histological findings distinguishing
invasiveness in lymph and blood vessels, thyroidal capsu-
lar invasion or extrathyroidal extension, low differentia-
tion of tumor cells, and multifocality are critical and may
influence therapeutic decisions and follow up. Most
patients in group A had such histological findings. More-
over in our study, a difference in papillary thyroid cancer
variants was observed between groups. The carcinoma
was entirely of the papillary type in 37.5% of patients in
group A and in 83.3% of group B; follicular variant of pap-
illary thyroid carcinoma was found in 62.5% and 16.7%
respectively. Consequently, we suggest that not all small
carcinomas should be grouped together based on size
alone, and the existence of two biological groups of
"apparently occult" papillary thyroid carcinomas, charac-
terized by a very different clinical behaviour, must be con-
sidered; the clinically apparent thyroid microcarcinoma
and the incidentally found thyroid carcinoma. The pres-
ence of lymph-nodes is obviously taken into account in
the classification and the therapy planning of thyroid
tumours as has recently been suggested in the recommen-
dations of both the American and the European Thyroid
Associations [16,29]. True incidental occult papillary car-
cinoma seemed to be different from non-incidental or
clinically apparent papillary microcarcinoma regarding
the main prognostic features [10,30-32]
Recent publications reveal that papillary microcarcinomas
with preoperatively detectable lymph node metastases
present with significantly more aggressive characteristics
than those with no metastases [33]. Four of our patients
in group A received additional radioactive iodine131I ther-
apy due to persistent local disease and 3 of the same group
presented with new cervical lymph nodes metastases (one
contralateral of the initial disease) 24–36 months after the
initial treatment, and received additional therapy with
radioactive iodine or underwent lymph node dissection.
Ito, in a recent publication [33], immunohistochemically
examined the expression of cell proliferation markers and
apoptotic markers in microcarcinoma patients with and
without clinically apparent metastases, and found that
cases with clinically apparent metastases showed
increased cyclin D1 expression together with decreased
p27 expression and higher levels of pRb and Ki-67 expres-
sion. These findings suggest that cases with clinically
apparent metastases show significantly higher growth
based on cell proliferation activity, apoptosis, and expres-
sion of metastatic suppressors than those demonstrating
no metastases.
Considering that some very small papillary thyroid carci-
nomas may give rise to recurrences and local or distant
metastases, we regard that their therapy should not be dif-
ferent than that reported for the larger ones, especially if
cervical lymph node metastasis was the reason for surgery.
In other words, total thyroidectomy and lymph node dis-
section [34-39] should be followed by suppressive thyrox-
ine therapy [40] and radioactive iodine ablation therapy
[41-43]. In cases of aggressive disease, the bilateral and
multifocal nature of otherwise occult primary disease
argues for total thyroidectomy. Ten of our patients of
group A had multifocal disease (in three of them the dis-
ease was bilateral). As most of the recurrences are in the
thyroid and the neck region, careful neck palpation sup-
plemented with high-resolution ultrasonography repre-
sents a useful surveillance strategy. During surgery, special
care should be given to the central lymph node compart-
ment, where the majority of lymph node metastases from
PTC has been reported [39,44,45]. Prophylactic lymph
Computed tomography of a patient (GK) with metastasis in  the parapharyngeal area from papillary thyroid microcarci- noma (for details see Table 1) Figure 1
Computed tomography of a patient (GK) with metastasis in 
the parapharyngeal area from papillary thyroid microcarci-
noma (for details see Table 1).Thyroid Research 2008, 1:8 http://www.thyroidresearchjournal.com/content/1/1/8
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node dissection of the central compartment should be
considered in patients who undergo thyroidectomy for
microcarcinomas and who present lateral lymph node
metastasis which are either known preoperatively by
ultrasonography or which are palpable during surgery [9].
Prophylactic node dissection was not shown to be benefi-
cial in patients without palpable lymphadenopathy, as
the recurrence rate did not differ between the prophylactic
lymph node dissection group (0.43%) and the no-dissec-
tion group (0.65%) [46]. It should be noted however, that
despite the local invasiveness and distant metastases of
these small carcinomas, the reported death is extremely
rare [47]. All our patients are still alive.
The majority of our patients of group B did not undergo cen-
tral lymph node dissection. However, during follow up
(range 38–130 months, median 106 months) no recurrence
in cervical lymph nodes or distant metastases appeared. In a
recent publication, the authors present the results of 317
patients who underwent surgery for benign diseases and
were found to have a papillary thyroid microcarcinoma
undetected by preoperative ultrasonography and fine-needle
aspiration biopsy. After the diagnosis of incidental papillary
thyroid carcinoma none of the patients underwent a comple-
tion central lymph node dissection. During follow up only
2.2% presented recurrent disease [45].
From this retrospective study, we conclude that papillary
microcarcinomas can be diagnosed after they have pro-
duced cervical lymph node metastases which may be the
first manifestation of the disease. Clinically apparent
lymph node metastasis is predictive of multifocality,
higher probability of extrathyroidal extension and a ten-
edency of recurrence. Therefore, when a lateral cervical
mass is present, despite the fact that the thyroid gland may
seem normal, a small thyroid carcinoma should be con-
sidered as likely. In the case of lesions that are suspicious
to be thyroid-derived, FNA of the lateral mass is usually
diagnostic, and is preferable to an open biopsy. Small
tumor size alone is not a reliable prognostic marker, and
treatment planning should be guided by histological find-
ings such as limitation of the tumor, invasiveness, or
lymph node metastases.
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